SEC Form 4 · accession 0001470831-26-000870
Klaviyo, Inc. · KVYO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ed Hallen
Director · 10% Owner
Period of report
Aug 31, 2026
Accepted (ET)
Sep 1, 2026 · 8:18 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001835830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common StockF2,F3 | Aug 31, 2026 | S | 39,167 | $20.47 | D | 94,457 | I | By Hodgkins Trust |
| Series A Common StockF4,F5 | Aug 31, 2026 | S | 59,615 | $20.49 | D | 465,631 | I | By Hodgkins LLC |
| Series A Common StockF5 | Aug 31, 2026 | G | 17,885 | $0.00 | D | 447,746 | I | By Hodgkins LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.30 to $20.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
- F6Represents a bona fide gift of 17,885 shares of stock from Hodgkins LLC, of which Reporting Person serves as manager, to a donor-advised fund pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.